Anti-SCN10A Antibody, clone 1J13 ZooMAb^® Rabbit Monoclonal

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Sodium channel protein type 10 subunit alpha (UniProt: Q9Y5Y9; also known as Peripheral nerve sodium channel 3, PN3, hPN3, Sodium channel protein type X subunit alpha, Voltage-gated sodium channel subunit alpha Nav1.8, Sodium Channel NaV1.8) is encoded by the SCN10A gene (Gene ID: 6336) in human. SCN10A is a tetrodotoxin-resistant sodium channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. The protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Its electrophysiological properties vary depending on the type of the associated beta subunits. SCN10A plays a critical role in the modulation of action potentials and is involved in the neuropathic pain mechanisms. It is a multi-pass membrane protein and is predominantly expressed in peripheral sensory neurons, particularly in dorsal root ganglia (DRG) and sciatic nerve. It can be translocated to the extracellular membrane through association with S100A10. Structurally, SCN10A features 4 homologous domains (internal repeats), each with 5 hydrophobic segments (S1,S2,S3,S5,S6) and one positively charged segment (S4). Segments S4 are probably the voltage-sensors and are characterized by a series of positively charged amino acids at every third position. Dysregulation or mutations in SCN10A have been linked to various pain disorders, including small fiber neuropathy and Brugada syndrome, a cardiac channelopathy characterized by an increased risk of arrhythmias. Recent studies have identified gain-of-function mutations in SCN10A that enhance pain sensitivity, while loss-of-function variants are associated with reduced pain perception, underscoring the gene′s pivotal role in pain modulation and cardiac health. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Huang, Y., et al. (2021). Hum Mol Genet. 31(2); 157-165; Chidiac, C., et al. (2021). Front Pharmacol. 12; 780132).

Quality Control Testing
Evaluated by Western Blotting in human spinal cord tissue lysate.
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected SCN10A in human spinal cord tissue lysate.
Tested Applications
Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected SCN10A in lysates from rat spinal cord and human dorsal root ganglia (DRG), and a 1:10,000 dilution from a representative lot detected SCN10A in lysates from SH-SY5Y cells and human brain tissue.

Affinity Binding Assay: A representative lot of this antibody bound SCN10A peptide with at least one thousand-fold (1,000X) higher affinity than with non-specific control peptide.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected SCN10A in SH-SY5Y cells.

Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected SCN10A in mouse spinal cord tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone 1J13 is a ZooMAb^® recombinant rabbit monoclonal antibody that specifically detects SCN10A. It targets an epitope within 24 amino acids from the C-terminal cytoplasmic domain.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

KLH-conjugated linear peptide corresponding to 24 amino acids from the C-terminal cytoplasmic domain of human SCN10A.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany